Phase 1 Alzheimer's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are between 65 and 85 years of age
• People who have been diagnosed with mild cognitive impairment or mild dementia due to Alzheimer's disease, based on specific 2018 diagnostic guidelines
• People who score 17 or higher on a standard memory and thinking test called the Montreal Cognitive Assessment (MoCA)
• People who have had a brain scan (called a PET amyloid scan, such as a Florbetaben scan) that showed amyloid deposits, performed within one year of joining the study
• People who are able to give their own consent or agreement to participate
• People who are willing and able to take part in all study-related activities and appointments
• People who have a reliable support person (such as a family member or close friend) who knows them well, has regular contact with them, and is available to attend clinic visits or be reached by phone

Who may not be able to join:

• People with a history of psychiatric conditions — such as hallucinations, major depression, thoughts of suicide, or delusions — that could interfere with completing study activities (as assessed by the lead doctor)
• People with a history of autoimmune disorders, conditions where the immune system attacks the body, severe asthma, or other serious infections or systemic illnesses (as assessed by the lead doctor)
• People who have used corticosteroids (steroid medications) or immune-suppressing drugs in the 30 days before joining the study
• People who have previously had their spleen removed
• People who have reduced kidney function
• People who have used chloroquine (a medication sometimes used for malaria or autoimmune conditions) within 8 weeks before joining the study
• People who are unable to have an MRI scan
• People who have had a mini-stroke (TIA), stroke, or seizures within the 12 months before screening
• People with any other neurological condition — apart from Alzheimer's disease — that could be affecting their thinking or memory, including possible effects from long COVID (as assessed by the lead doctor)
• People who are currently participating in another Alzheimer's disease clinical trial that involves an investigational treatment
• People who are currently taking blood-thinning (anticoagulant) medication
• People who are currently taking certain medications that are processed by a specific liver enzyme called CYP1A2 (confirm with trial site for a list of affected medications)
• People who have been exposed to COVID-19 infection within the past 14 days, or who have had recent symptoms that may be related to COVID-19 within the past 14 days

Important: Always verify eligibility with the trial site directly before applying.